Point-of-Care Biopsy Market
Report ID: SQMIG35A4636
Report ID: SQMIG35A4636
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A4636 |
Region:
Global |
Published Date: November, 2026
Pages:
157
|Tables:
122
|Figures:
77
Global Point-Of-Care Biopsy Market size was valued at USD 1.45 Billion in 2024 and is poised to grow from USD 1.58 Billion in 2025 to USD 3.13 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).
The primary driver of the global point‑of‑care biopsy market is the accelerating demand for invasive diagnostic solutions that can be performed at the bedside or in outpatient settings. As healthcare systems shift toward value‑based care, clinicians seek to reduce turnaround time for histopathology results, which traditionally require centralized labs and days of delay. Point‑of‑care platforms, such as handheld needle‑core devices and DNA sequencers, have emerged to meet this need, allowing immediate tissue acquisition and preliminary analysis. Over the past decade, adoption has grown from niche oncology clinics to mainstream hospitals, propelled by pilot studies that demonstrated faster treatment decisions and lower patient anxiety. The second pivotal factor shaping the global point‑of‑care biopsy market is the convergence of molecular profiling technologies with decentralized testing infrastructure, which creates a fertile environment for personalized therapy. As oncology moves toward targeted agents, physicians need on‑site access to genetic and immunohistochemical data; integrating sequencing modules into biopsy kits shortens the interval between sample collection and actionable insight. A lung‑cancer clinic in Texas reduced the median time to EGFR mutation reporting from ten days to under 24 hours, enabling same‑day initiation of tyrosine‑kinase inhibitors. This cause‑and‑effect chain fuels demand for devices, draws investment, and opens export opportunities in emerging markets where centralized pathology services are scarce.
How is AI integration accelerating diagnostic accuracy in the point‑of‑care biopsy market?
AI integration is reshaping point of care biopsy by embedding real time image analysis directly into handheld sampling tools. The technology interprets tissue morphology, flags suspicious regions and suggests diagnoses while the clinician holds the specimen. Today several manufacturers embed neural networks into cartridge based platforms that deliver results within minutes, reducing reliance on central labs. This shift accelerates clinical decision making and expands access in outpatient clinics and remote settings. Early adopters report smoother workflows, fewer repeat procedures and higher confidence in early cancer detection. The market is responding with increased investment in AI driven hardware and software partnerships.PathAI announced a collaboration with Roche in June 2023, bringing an AI powered diagnostic engine to the company’s point of care biopsy platform. The joint solution shortens analysis time, improves tissue classification and demonstrates how AI can boost accuracy while expanding market adoption.
Market snapshot - (2026-2033)
Global Market Size
USD 1.45 Billion
Largest Segment
Consumables & Accessories
Fastest Growth
Point-of-Care Biopsy Analysis Systems
Growth Rate
8.9% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global point-of-care biopsy market is segmented by product type, biopsy technique, application, end user and region. Based on product type, the market is segmented into Biopsy Instruments, Biopsy Needles & Sampling Devices, Rapid Sample Preparation Systems, Point-of-Care Biopsy Analysis Systems and Consumables & Accessories. Based on biopsy technique, the market is segmented into Fine-Needle Aspiration, Core Needle Biopsy, Punch Biopsy and Other Biopsy Techniques. Based on application, the market is segmented into Oncology, Dermatology, Infectious Diseases and Other Diagnostic Applications. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
What role do biopsy needles and sampling devices play in advancing point of care biopsy workflows? |@12
Biopsy Needles & Sampling Devices segment dominates because they provide the essential physical interface for acquiring tissue, enabling clinicians to perform reliable procedures with minimal invasiveness. Their design flexibility supports multiple techniques, and ongoing material innovations improve durability and patient comfort. Clinicians prioritize these devices for accuracy and repeatability, driving consistent procurement across hospitals and clinics, thereby cementing their central role in the point of care biopsy ecosystem and operational efficiency throughout.
Meanwhile, Point of Care Biopsy Analysis Systems are emerging as the key high growth area in the point of care biopsy market. Integration of miniaturized spectroscopy and AI driven interpretation is expanding on site diagnostic capability, reducing turnaround time and reliance on labs. This acceleration fuels broader adoption of decentralized testing, opening new revenue streams and clinical pathways.
how is core needle biopsy addressing accuracy challenges in point of care diagnostic settings? |@12
Core Needle Biopsy segment dominates because it balances tissue volume and procedural safety, delivering samples sufficient for histopathology while minimizing patient discomfort. Its adaptability to various organ systems ensures wide clinical utility, and robust evidence of diagnostic accuracy reinforces physician confidence. Continued refinements in needle geometry and imaging guidance further enhance yield, making it the preferred choice across oncology and dermatology workflows in point of care settings.
On the other hand, Fine Needle Aspiration is witnessing the strongest growth momentum in the point of care biopsy market. Improved cytological techniques and real time imaging are increasing diagnostic confidence while reducing invasiveness. These advances broaden its appeal for rapid assessments in infectious disease and dermatology, accelerating market expansion and encouraging investment in portable aspiration platforms.
To get detailed segments analysis, Request a Free Sample Report
Why does North America Dominate the Global Point-of-Care Biopsy Market? |@12
North America leads the market through a combination of advanced healthcare infrastructure, robust research ecosystems, and supportive regulatory frameworks that encourage rapid adoption of innovative diagnostics. The presence of leading academic medical centers and technology-focused venture environments fuels continuous development of portable biopsy platforms. Strong reimbursement pathways and collaborative networks among clinicians, laboratories, and device manufacturers accelerate integration of point-of-care solutions into routine practice. Moreover, patient‑centric care models in the region prioritize timely diagnosis, creating sustained demand for rapid, accurate biopsy technologies. The convergence of high clinical expertise, strategic public‑private partnerships, and a culture of early technology adoption underpins the region’s dominant position.
United States Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market activity in the United States is driven by extensive clinical research networks and widespread implementation of precision medicine initiatives. Healthcare providers prioritize rapid diagnostic turnaround, encouraging hospitals and outpatient centers to integrate portable biopsy tools. Strong funding mechanisms for innovation and a dynamic start‑up environment further reinforce the market’s growth, while collaborative efforts between academic institutions and industry accelerate product refinement and adoption.
Canada Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market momentum in Canada is supported by a publicly funded health system that emphasizes equitable access to advanced diagnostics. Provincial health authorities actively explore cost‑effective technologies that reduce patient travel and improve diagnostic timelines. Partnerships between research hospitals and technology firms foster localized development and validation of portable biopsy solutions, aligning with national health priorities focused on early detection and integrated care pathways.
What is Driving the Rapid Expansion of Point-of-Care Biopsy Market in Europe? |@12
Europe’s expansion is propelled by strong governmental health initiatives that prioritize early detection and streamlined patient pathways across member states. Collaborative research programs among leading universities and medical centers generate a fertile environment for technology transfer and clinical validation of point-of-care biopsy devices. Regulatory harmonization facilitates market entry, while reimbursement models that reward diagnostic efficiency encourage healthcare providers to adopt these tools. Additionally, a growing emphasis on personalized treatment strategies and cross‑border healthcare networks amplifies demand for rapid, accurate tissue analysis, positioning Europe as a dynamic hub for market growth.
Germany Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market in Germany benefits from its robust medical device manufacturing base and rigorous clinical evaluation standards. The country’s integrated care networks and emphasis on precision oncology drive hospitals to incorporate rapid biopsy solutions. Strong collaborations between research institutes and industry accelerate innovation cycles, ensuring that clinicians have access to state‑of‑the‑art diagnostic tools that align with national health objectives.
United Kingdom Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market momentum in the United Kingdom is accelerated by national strategies that focus on early cancer detection and digital health transformation. The National Health Service promotes the adoption of portable diagnostic platforms to enhance patient pathways, while academic health science centres spearhead clinical trials that validate emerging technologies. This synergistic environment fuels rapid market uptake and continuous innovation.
France Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market development in France is emerging through supportive public health policies that encourage innovative diagnostic solutions. Collaborative frameworks between regional hospitals and biotech clusters facilitate the testing and integration of portable biopsy devices. The French healthcare system’s focus on improving diagnostic speed and patient experience underpins growing interest in point‑of‑care technologies.
How is Asia Pacific Strengthening its Position in Point-of-Care Biopsy Market? |@12
Asia Pacific is advancing its role by leveraging a blend of rapid technological adoption, expanding healthcare infrastructure, and increasing focus on early disease detection across its economies. Regional collaborations between governmental health agencies and private innovators create pathways for accelerated development and regulatory approval of point-of-care biopsy platforms. The growing prevalence of outpatient diagnostic centers and a cultural emphasis on timely medical intervention drive demand for compact, user‑friendly biopsy solutions. Investment in digital health ecosystems and cross‑border knowledge exchange further enhances the region’s capacity to integrate cutting‑edge diagnostic tools into routine clinical practice, positioning Asia Pacific as a rising contributor to the global market.
Japan Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market activity in Japan is supported by a mature healthcare system that values precision diagnostics and technological excellence. Leading medical universities partner with device manufacturers to conduct extensive clinical validations, fostering trust among clinicians. The national emphasis on minimally invasive procedures and rapid result delivery aligns closely with the capabilities of point‑of‑care biopsy technologies, encouraging broad adoption across hospitals and specialized clinics.
South Korea Point-of-Care Biopsy Market |@12
Point-of-Care Biopsy Market growth in South Korea is propelled by a dynamic biotech sector and proactive health policies that prioritize early detection. Hospitals integrate portable biopsy tools to streamline workflows and reduce patient wait times. Strong government incentives for medical innovation, combined with a fast‑adopting clinical community, create an environment where point‑of‑care diagnostics rapidly become standard components of cancer care pathways.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers |@12
Rapid Adoption of Minimally Invasive Techniques
Increasing Demand for Real-Time Diagnostics
Restraints |@12
High Cost of Point‑of‑Care Devices
Regulatory Hurdles Across Regions
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by incumbents accelerating M&A activity, forging strategic partnerships with diagnostic laboratories, and investing in AI‑driven imaging platforms to shorten turnaround times; recent joint ventures between major device manufacturers and cloud‑analytics firms illustrate how technology integration is becoming a key market driver, while acquisitions of niche molecular assay developers are consolidating capabilities across the point‑of‑care biopsy value chain.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the global point‑of‑care biopsy market is projected to double by 2033, driven first by the accelerating demand for minimally invasive techniques that let clinicians obtain tissue quickly at the bedside and reduce patient discomfort. A second important catalyst is the growing need for real‑time diagnostics, especially as personalized oncology relies on immediate molecular data to guide therapy. North America remains the dominant region thanks to its advanced health‑care infrastructure, strong reimbursement pathways and early‑adopter culture. The Biopsy Needles & Sampling Devices segment leads the market because it provides the essential interface for reliable tissue acquisition. However, high upfront costs of point‑of‑care devices act as a restraint, slowing adoption in cost‑sensitive settings.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.45 Billion |
| Market size value in 2033 | USD 3.13 Billion |
| Growth Rate | 8.9% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Point-of-Care Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Point-of-Care Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Point-of-Care Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Point-of-Care Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
